US 2021/0171635 A1Published application

Antibodies to ICOS

AssigneeJounce Therapeutics, Inc.

InventorsStephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek

Life of this patent

Estimating the term…

Abstract

Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.

Claims28

Dependent claims

An isolated antibody that binds to ICOS, wherein the antibody comprises:

i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
42;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
43;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
44;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
45;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
46;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
47;
or
ii) (a) HCDR1 comprising an amino acid sequence selected from SEQ ID NOs:
32, 162, 172, and 182;
(b) HCDR2 comprising an amino acid sequence selected from SEQ ID NOs:
33, 163, 173, and 183;
(c) HCDR3 comprising an amino acid sequence selected from SEQ ID NOs:
34, 164, 174, and 184;
(d) LCDR1 comprising an amino acid sequence selected from SEQ ID NOs:
35, 165, 175, and 185;
(e) LCDR2 comprising an amino acid sequence selected from SEQ ID NOs:
36, 166, 176, and 186;
and (f) LCDR3 comprising an amino acid sequence selected from SEQ ID NOs:
37, 167, 177, and 187;
or
iii) (a) HCDR1 comprising an amino acid sequence selected from SEQ ID NOs:
52, 122, 132, 142, and 152;
(b) HCDR2 comprising an amino acid sequence selected from SEQ ID NOs:
53, 123, 133, 143, and 153;
(c) HCDR3 comprising an amino acid sequence selected from SEQ ID NOs:
54, 124, 134, 144, and 154;
(d) LCDR1 comprising an amino acid sequence selected from SEQ ID NOs:
55, 125, 135, 145, and 155;
(e) LCDR2 comprising an amino acid sequence selected from SEQ ID NOs:
56, 126, 136, 146, and 156;
and (f) LCDR3 comprising an amino acid sequence selected from SEQ ID NOs:
57, 127, 137, 147, and 157;
or
iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
22;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
23;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
24;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
25;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
26;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
27;
or
v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
32;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
33;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
34;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
35;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
36;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
37;
or
vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
52;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
53;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
54;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
55;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
56;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
57;
or
vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
122;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
123;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
124;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
125;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
126;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
127;
or
viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
132;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
133;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
134;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
135;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
136;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
137;
or (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
142;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
143;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
144;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
145;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
146;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
147;
or
ix (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
152;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
153;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
154;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
155;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
156;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
157;
or
x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
162;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
163;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
164;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
165;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
166;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
167;
or
xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
172;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
173;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
174;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
175;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
176;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
177;
or
xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
182;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
183;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
184;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
185;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
186;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
187.

164 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/022,856Filed 16 Sep 2020
Priority: 23 Mar 2015
Published: 10 Jun 2021
Term ends: Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61P 35/00
Antineoplastic agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
A61K 2039/507
Comprising antibodies: comprising a combination of two or more separate antibodies

Family

Application62/137,034Us provisional application · filed 23 Mar 2015
Application62/147,484Us provisional application · filed 14 Apr 2015
Application62/156,588Us provisional application · filed 4 May 2015
Application62/242,489Us provisional application · filed 16 Oct 2015
Application62/255,635Us provisional application · filed 16 Nov 2015
Application15/076,867Division · filed 22 Mar 2016
Application16/012,867Division · filed 20 Jun 2018
Application16/745,066Continuation · filed 16 Jan 2020
Application17/022,856Continuation
Application16/745,066Division
US 10,023,635 B2Related patent
US 10,570,203 B2Related patent
US 2016/0304610 A1Published application
US 2018/0355041 A1Published application
US 2021/0171635 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

An isolated antibody that binds to ICOS, wherein the antibody comprises:

i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
42;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
43;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
44;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
45;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
46;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
47;
or
ii) (a) HCDR1 comprising an amino acid sequence selected from SEQ ID NOs:
32, 162, 172, and 182;
(b) HCDR2 comprising an amino acid sequence selected from SEQ ID NOs:
33, 163, 173, and 183;
(c) HCDR3 comprising an amino acid sequence selected from SEQ ID NOs:
34, 164, 174, and 184;
(d) LCDR1 comprising an amino acid sequence selected from SEQ ID NOs:
35, 165, 175, and 185;
(e) LCDR2 comprising an amino acid sequence selected from SEQ ID NOs:
36, 166, 176, and 186;
and (f) LCDR3 comprising an amino acid sequence selected from SEQ ID NOs:
37, 167, 177, and 187;
or
iii) (a) HCDR1 comprising an amino acid sequence selected from SEQ ID NOs:
52, 122, 132, 142, and 152;
(b) HCDR2 comprising an amino acid sequence selected from SEQ ID NOs:
53, 123, 133, 143, and 153;
(c) HCDR3 comprising an amino acid sequence selected from SEQ ID NOs:
54, 124, 134, 144, and 154;
(d) LCDR1 comprising an amino acid sequence selected from SEQ ID NOs:
55, 125, 135, 145, and 155;
(e) LCDR2 comprising an amino acid sequence selected from SEQ ID NOs:
56, 126, 136, 146, and 156;
and (f) LCDR3 comprising an amino acid sequence selected from SEQ ID NOs:
57, 127, 137, 147, and 157;
or
iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
22;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
23;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
24;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
25;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
26;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
27;
or
v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
32;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
33;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
34;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
35;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
36;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
37;
or
vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
52;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
53;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
54;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
55;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
56;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
57;
or
vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
122;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
123;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
124;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
125;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
126;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
127;
or
viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
132;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
133;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
134;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
135;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
136;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
137;
or (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
142;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
143;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
144;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
145;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
146;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
147;
or
ix (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
152;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
153;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
154;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
155;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
156;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
157;
or
x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
162;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
163;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
164;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
165;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
166;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
167;
or
xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
172;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
173;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
174;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
175;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
176;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
177;
or
xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:
182;
(b) HCDR2 comprising the amino acid sequence of SEQ ID NO:
183;
(c) HCDR3 comprising the amino acid sequence of SEQ ID NO:
184;
(d) LCDR1 comprising the amino acid sequence of SEQ ID NO:
185;
(e) LCDR2 comprising the amino acid sequence of SEQ ID NO:
186;
and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:
187.

164 more elements

Facts

Application

17/022,856Filed 16 Sep 2020

Priority

23 Mar 2015

Published

10 Jun 2021

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 16/2818
Against the immunoglobulin superfamily: against CD28 or CD152
A61P 35/00
Antineoplastic agents
A61K 2039/505
Medicinal preparations containing antigens or antibodies: comprising antibodies
A61K 2039/507
Comprising antibodies: comprising a combination of two or more separate antibodies

Family

Application62/137,034Us provisional application · filed 23 Mar 2015

Application62/147,484Us provisional application · filed 14 Apr 2015

Application62/156,588Us provisional application · filed 4 May 2015

Application62/242,489Us provisional application · filed 16 Oct 2015

Application62/255,635Us provisional application · filed 16 Nov 2015

Application15/076,867Division · filed 22 Mar 2016

Application16/012,867Division · filed 20 Jun 2018

Application16/745,066Continuation · filed 16 Jan 2020

Application17/022,856Continuation

Application16/745,066Division

US 10,023,635 B2Related patent

US 10,570,203 B2Related patent

US 2016/0304610 A1Published application

US 2018/0355041 A1Published application

US 2021/0171635 A1This patent

From the US filing history. Foreign family members aren’t listed.